Humacyte, Inc.

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable, bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. Humacyte currently develops and manufactures acellular tissues to address life- and limb-threatening vascular conditions while focusing on potential future applications for complex tissue and organ diseases. Located in Durham, N.C., the company was founded in 2004 by Laura Niklason, MD, Ph.D., a world leader in tissue engineering and the Chief Executive Officer of Humacyte, along with Drs. Juliana Blum and Shannon Dahl.